Fundraising Fox
🦊/Companies
Sign in

Alpine Immune Sciences

Seattle, US · Founded 2014 · Delaware corporation · 29 employees on LinkedIn · 8 known investors

Find your way into Alpine Immune Sciences

Biotech

Founders & leadership

Alpine Immune Sciences was founded in 2014 by Mitchell Gold.

MGMitchell Gold
Mitchell GoldinCo-founder Executive Chairman and CEO2015–2024Venture Partner at Frazier Life Sciences
MK
Michael KornackerinCo-founder and VP Protein Engineering2015–2017Michael Kornacker is co-founder and executive officer of Alpine Immune Sciences, developing clinical-stage biopharmaceuticals. He spent two decades at Bristol-Myers Squibb and Amgen working on protein engineering and directed evolution for drug development, and holds multiple patents and publications in the field.
RS
Ryan SwansoninCo-Founder, Vice President Immunology2015–2019Ryan Swanson has over 25 years of experience in biologic therapeutics development, including discovery research roles at both large pharmaceutical companies and startups, with expertise in protein engineering and computational drug design.
DM
David MillerinDirector of Corporate Affairs2015–2019David Miller is an executive officer and director at Alpine Immune Sciences with over 25 years of experience in corporate strategy and business communications across multiple company stages, from early-stage ventures to public offerings, including two exits exceeding $1 billion and two IPOs. He has specialized in technology and biotechnology sector analysis and investor relations.
JPJames Paul Rickey
James Paul RickeySenior Vice President and Chief Financial Officer
MJ
Mark James LittonPresident and Chief Operating Officer
TS
Tom SokolowskiExecutive
JV
Jay VenkatesanNamed on SEC filing
PTPeter Thompson
Peter ThompsoninNamed on SEC filingGeneral Partner at OrbiMed
CPChristopher Peetz
Christopher PeetzinNamed on SEC filingEntrepreneur-in-Residence at Frazier Life Sciences
RC
Robert ConwayNamed on SEC filing
PSPaul Sekhri
Paul Sekhriin𝕏Board Director2017–2020Investor at eGenesis, Inc. Full-time

Investors · 8

Decheng CapitalMenlo Park
Frazier Life SciencesPalo Altovia James N. Topper · led
Biotechnology Value Fundreported · 2 sourcesSan Francisco
OrbiMedreportedNew York · $1M – $75M

Also in the syndicate · 4

Avidity PartnersLogos CapitalOmega FundTCG X

Reported raises · per SEC filings

Form D private placements

$234.9M disclosed across 7 rounds · 2014–2021

▶$91MraisedSep 2021 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stanford PengExecutive Officer
  • Robert ConwayDirector
  • Peter ThompsonDirector
  • Jay VenkatesanDirector
  • Zelanna GoldbergExecutive Officer
  • Natasha HerndayDirector
  • James Paul RickeyExecutive Officer
  • Cui XiangminDirector
  • Mitchell GoldExecutive Officer, Director
  • James TopperDirector
  • Christopher PeetzDirector
Offering amount
$91M
Amount sold
$91M
First sale
Sep 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60MraisedAug 2020 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert ConwayDirector
  • Paul SekhriDirector
  • Cui XiangminDirector
  • James TopperDirector
  • Jay VenkatesanDirector
  • James Paul RickeyExecutive Officer
  • Peter ThompsonDirector
  • Mitchell GoldExecutive Officer, Director
  • Stanford PengExecutive Officer
  • Christopher PeetzDirector
Offering amount
$82.7M
Amount sold
$60M
Sales commissions
$3.3M
Placement agents
Oppenheimer & Co. Inc., Cowen and Company
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.3MraisedJan 2019 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jay VenkatesanDirector
  • James Paul RickeyExecutive Officer
  • Mitchell GoldExecutive Officer, Director
  • James TopperDirector
  • Mark James LittonExecutive Officer
  • Cui XiangminDirector
  • Peter ThompsonDirector
  • Christopher PeetzDirector
  • Robert ConwayDirector
  • Stanford PengExecutive Officer
  • Paul SekhriDirector
Offering amount
$48.7M
Amount sold
$25.3M
Sales commissions
$907.5K
Finders' fees
$75K
Placement agents
Piper Jaffray & Co.
First sale
Jan 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17MraisedJul 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Stanford PangExecutive Officer
  • Peter ThompsonDirector
  • Mitchell H. GoldExecutive Officer, Director
  • Jay VenkatesanExecutive Officer, Director
  • J. Paul RickeyExecutive Officer
  • James TopperDirector
Offering amount
$17M
Amount sold
$17M
First sale
Jul 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.3MraisedJun 2016 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan SwansonExecutive Officer
  • Peter ThompsonDirector
  • Mitchell H. GoldExecutive Officer, Director
  • Jay VenkatesanExecutive Officer, Director
  • James TopperDirector
  • David MillerExecutive Officer
  • Michael KornackerExecutive Officer
Offering amount
$48M
Amount sold
$10.3M
First sale
Jun 2016
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedMay 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dr. Mitchell H GoldExecutive Officer, Director
  • Michael KornackerExecutive Officer, Director
  • Ryan SwansonExecutive Officer, Director
  • David MillerExecutive Officer, Director
Offering amount
$1.3M
Amount sold
$1.3M
First sale
Jan 2015
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30MraisedNov 2014 · 12 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan LeffDirector
  • Tom SokolowskiExecutive Officer
  • Howard FurstDirector
  • Evan LohDirector
  • John MooreDirector
  • Joseph LoscalzoDirector
Offering amount
$40M
Amount sold
$30M
Finders' fees
$845.6K
First sale
Nov 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Alpine Immune Sciences went on to found or lead other companies.

Chris PeetzDirectorFounded Mirum PharmaceuticalsPaul SekhriBoard DirectorFounded Vtvtherapeutics

Acquisitions · 1

Early investors' stakes continue via these deals
Nivalis

Nivalis Therapeutics was a Boulder, Colorado clinical-stage biopharmaceutical company developing cavosonstat, an oral GSNOR inhibitor for cystic fibrosis, which failed its Phase 2 trial.

In the news

Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ...finance.yahoo.com · May 2024Alpine Immune Sciences Raising $100M in Public Offering | Life Science Washingtonlifesciencewa.org · Sep 2022Seattle Biotech Alpine Immune Sciences Raises $91M for Drug Development | Life Science Washingtonlifesciencewa.org · Sep 2021Alpine raises $91M to fuel the Seattle biotech's clinical trials for lupus and cancer – GeekWiregeekwire.com · Sep 2021Alpine Immune Sciences raises $48 million for cancer and autoimmune treatmentgeekwire.com · Jun 2016

Frequently asked questions

Who founded Alpine Immune Sciences?
Alpine Immune Sciences was founded by Mitchell Gold in 2014.
Who are Alpine Immune Sciences's investors?
Alpine Immune Sciences's investors include Decheng Capital, Frazier Life Sciences, Biotechnology Value Fund, OrbiMed.
How much funding has Alpine Immune Sciences raised?
Alpine Immune Sciences has disclosed $234.9M raised across 7 rounds.
Where is Alpine Immune Sciences headquartered?
Alpine Immune Sciences is headquartered in Seattle, US.